Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07416188 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorStudy Status, Study Description, Eligibilityv107
Show 44 earlier versionsHide 44 earlier versions
MinorStart date changed from estimate of Jul 22, 2026 to Jul 15, 2026v106
MinorStart date: Jul 21, 2026 to Jul 22, 2026v105
MinorStart date: Jul 20, 2026 to Jul 21, 2026v104
MinorStart date: Jul 19, 2026 to Jul 20, 2026v103
MinorStart date: Jul 16, 2026 to Jul 19, 2026v102
MinorStart date: Jul 15, 2026 to Jul 16, 2026v101
MinorStart date: Jul 14, 2026 to Jul 15, 2026v100
MinorStart date: Jul 13, 2026 to Jul 14, 2026v99
MinorStart date: Jul 12, 2026 to Jul 13, 2026v98
MinorStart date: Jul 8, 2026 to Jul 12, 2026v97
MinorStart date: Jul 7, 2026 to Jul 8, 2026v96
MinorStart date: Jul 6, 2026 to Jul 7, 2026v95
MinorStart date: Jul 5, 2026 to Jul 6, 2026v94
MinorStart date: Jul 2, 2026 to Jul 5, 2026v93
MinorStart date: Jul 1, 2026 to Jul 2, 2026v92
MinorStart date: Jun 30, 2026 to Jul 1, 2026v91
MinorStart date: Jun 29, 2026 to Jun 30, 2026v90
MinorStart date: Jun 28, 2026 to Jun 29, 2026v89
MinorStart date: Jun 24, 2026 to Jun 28, 2026v88
MinorStart date: Jun 23, 2026 to Jun 24, 2026v87
MinorStart date: Jun 22, 2026 to Jun 23, 2026v86
MinorStart date: Jun 21, 2026 to Jun 22, 2026v85
MinorStart date: Jun 18, 2026 to Jun 21, 2026v84
MinorStart date: Jun 17, 2026 to Jun 18, 2026v83
MinorStart date: Jun 16, 2026 to Jun 17, 2026v82
MinorStart date: Jun 15, 2026 to Jun 16, 2026v81
MinorStart date: Jun 14, 2026 to Jun 15, 2026v80
MinorStart date: Jun 11, 2026 to Jun 14, 2026v79
MinorStart date: Jun 10, 2026 to Jun 11, 2026v78
MinorStart date: Jun 9, 2026 to Jun 10, 2026v77
MinorStart date: Jun 8, 2026 to Jun 9, 2026v76
MinorStart date: Jun 7, 2026 to Jun 8, 2026v75
MinorStart date: Jun 4, 2026 to Jun 7, 2026v74
MinorStart date: Jun 3, 2026 to Jun 4, 2026v73
MinorStart date: Jun 2, 2026 to Jun 3, 2026v72
MinorStart date: Jun 1, 2026 to Jun 2, 2026v71
MinorStart date: May 28, 2026 to Jun 1, 2026v70
MinorStart date: May 27, 2026 to May 28, 2026v69
MinorStart date: May 26, 2026 to May 27, 2026v68
MinorStart date: May 25, 2026 to May 26, 2026v67
MinorStart date: May 24, 2026 to May 25, 2026v66
MinorStart date: May 21, 2026 to May 24, 2026v65
MinorStart date: May 20, 2026 to May 21, 2026v64
MinorStart date: May 19, 2026 to May 20, 2026v63
NotableRecruitment openedStart date: May 18, 2026 to May 19, 2026v62Show 1 more changeShow less
Start date: May 18, 2026 to May 19, 2026
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Background:
Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often fatal. Researchers want to know if a study drug (LMP744) can kill glioblastoma tumor cells.
Objective:
To test LMP744 in people with glioblastoma.
Eligibility:
People aged 18 years or older with glioblastoma that returned after treatment.
Design:
Participants will be screened. They will have a surgery to remove a small sample of tumor tissue (biopsy) from the brain. This will be done under protocol 03-N-0164. They will stay in the clinic for 1 night. They will also have imaging scans and tests of their heart function.
Participants will have a central line installed: A flexible tube will be inserted into a vein in the chest. It will be attached to a "port" under the skin. This port will be used to draw blood and give medicines without having to insert new needles into a vein.
LMP744 will be given through the central line for 5 days in a row. Participants will remain in the clinic for this time.
Participants will then have a second surgery to remove as much of their tumor as possible. They will remain in the clinic until they recover from the surgery. Then they will recover at home after surgery.
Participants will return to the clinic to receive the study drug for 5 days in a row through the central line, once a month for up to 12 months. Blood tests, heart function tests, and periodic imaging scans will be repeated during these visits.
Participants will continue to have telehealth visits every 3 months after they stop taking the drug.